Inventor · disambiguated record
Stephanos Ioannidis
Also filed as: IOANNIDIS JR STEPHANOS · IOANNIDIS STEPHANOS
39 granted patents·18 pending applications·350 citations·filing 2004–2021
98Inventor score
Files withFORMA THERAPEUTICS INC23ASTRAZENECA AB14VALO EARLY DISCOVERY INC11VALO HEALTH INC4FENG XIAOMEI2
Top patents by PatentIndex Score
57 records- 0197US9840491B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Dec 12, 2017·22 cites·17 claims
- 0296US10377767B2Thienopyrimidinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·16 cites·16 claims
- 0396US10377773B2Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·18 cites·16 claims
- 0496US10000495B2Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Jun 19, 2018·21 cites·16 claims
- 0596US9938300B2Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Apr 10, 2018·23 cites·15 claims
- 0696US9932351B2Thienopyrimidinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Apr 3, 2018·24 cites·12 claims
- 0796US9902728B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Feb 27, 2018·24 cites·40 claims
- 0895US10934299B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Mar 2, 2021·7 cites·20 claims
- 0995US10377760B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·17 cites·20 claims
- 1095US10351571B2Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Jul 16, 2019·15 cites·17 claims
- 1195US9248140B2Chemical compoundsASTRAZENECA AB·Filed 2015·Granted Feb 2, 2016·31 cites·6 claims
- 1294US10519129B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 31, 2019·8 cites·21 claims
- 1394US10519127B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 31, 2019·8 cites·24 claims
- 1494US10519130B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 31, 2019·8 cites·21 claims
- 1594US10519128B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 31, 2019·8 cites·19 claims
- 1694US10513507B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2017·Granted Dec 24, 2019·9 cites·20 claims
- 1794US10513508B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·8 cites·30 claims
- 1894US10508098B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 17, 2019·8 cites·20 claims
- 1993US10906916B2Thienopyrimidinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Feb 2, 2021·4 cites·16 claims
- 2093US9018381B2Chemical compoundsDIEBOLD ROBERT BRUCE·Filed 2011·Granted Apr 28, 2015·39 cites·8 claims
- 2188US11247987B2Inhibiting ubiquitin specific peptidase 30FORMA THERAPEUTICS INC·Filed 2018·Granted Feb 15, 2022·3 cites·24 claims
- 2288US10836741B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 17, 2020·3 cites·28 claims
- 2387US10927130B2Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Feb 23, 2021·4 cites·16 claims
- 2485US10981915B2Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Apr 20, 2021·3 cites·12 claims
- 2583US10889592B2Thienopyrazine carboxamides as ubiquitin-specific protease inhibitorsVALO EARLY DISCOVERY INC·Filed 2017·Granted Jan 12, 2021·2 cites·28 claims
- 2683US10399980B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 3, 2019·2 cites·11 claims
- 2783US10189841B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Jan 29, 2019·3 cites·11 claims
- 2882US11524966B1Carboxamides as ubiquitin-specific protease inhibitorsVALO EARLY DISCOVERY INC·Filed 2018·Granted Dec 13, 2022·2 cites·15 claims
- 2981US11161848B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 2, 2021·1 cites·26 claims
- 3080US10913753B2Thienopyridine carboxamides as ubiquitin-specific protease inhibitorsFORMA THERAPEUTICS INC·Filed 2017·Granted Feb 9, 2021·2 cites·20 claims
- 3177US8088784B24-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancerFENG XIAOMEI·Filed 2010·Granted Jan 3, 2012·4 cites·6 claims
- 3276US11739071B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2020·Granted Aug 29, 2023·0 cites·20 claims
- 3375US12043623B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2021·Granted Jul 23, 2024·0 cites·20 claims
- 3474US8486966B29-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancerDAVIES AUDREY·Filed 2008·Granted Jul 16, 2013·2 cites·4 claims
- 3573US11795171B2Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitorsVALO HEALTH INC·Filed 2021·Granted Oct 24, 2023·0 cites·10 claims
- 3672US12018030B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsVALO HEALTH INC·Filed 2021·Granted Jun 25, 2024·0 cites·16 claims
- 3772US2021292337A1Thienopyrimidinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2021·Application pending·0 cites
- 3871US2021323978A1Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2021·Application pending·0 cites
- 3967US2022185806A1Inhibiting ubiquitin specific peptidase 30FORMA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4062US11325917B2Thienopyrazine carboxamides as ubiquitin-specific protease inhibitorsVALO HEALTH INC·Filed 2020·Granted May 10, 2022·0 cites·20 claims
- 4161US7423061B2Substitute thiophenes and uses thereofASTRAZENECA AB·Filed 2004·Granted Sep 9, 2008·1 cites·17 claims
- 4261US2009054396A1Substituted thiophenes and uses thereofASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 4357US2010204231A1Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancerASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 4456US2015011545A1Chemical Compounds - 759ASTRAZENECA AB·Filed 2014·Application pending·0 cites
- 4555US2016176906A1Chemical CompoundsASTRAZENECA AB·Filed 2015·Application pending·0 cites
- 4654US2008287475A14-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of CancerASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 4754US2014155394A1Chemical Compounds - 759ASTRAZENECA AB·Filed 2013·Application pending·0 cites
- 4853US2011201628A1Heterocyclic jak kinase inhibitorsCHUAQUI CLAUDIO EDMUNDO·Filed 2009·Application pending·0 cites
- 4951US2022213059A1Inhibiting usp19VALO HEALTH INC·Filed 2020·Application pending·0 cites
- 5050US12162888B2Carboxamides as ubiquitin-specific protease inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Dec 10, 2024·0 cites·15 claims
Showing the top 50 of 57 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →